Angiodynamics Inc (ANGO) · Oct 8, 2026 · Earnings
Beat — Adjusted EPS $(0.04) vs roughly $(0.11)–$(0.12) consensus
AngioDynamics’ earnings beat on adjusted EPS, with Med Tech growth accelerating while legacy Med Device remains nearly flat and leadership changes.
AngioDynamics is in the middle of a deliberate shift from its slower legacy Med Device portfolio toward higher-growth platforms—Auryon, mechanical thrombectomy, and NanoKnife. Med Tech grew 18.4% in fiscal 2026 versus 2.6% for Med Device, so the key question entering this quarter was whether that mix shift could keep producing growth and improving profitability.
| Metric | Q1 FY27 | Q1 FY26 | Comparison |
|---|---|---|---|
| Net sales | $80.9M | $75.7M | +6.9% |
| Med Tech sales | $39.9M | $35.3M | +13.2% |
| Med Device sales | $41.0M | $40.5M | +1.4% |
| Adjusted EPS | $(0.04) | $(0.10) | Improved |
| Adjusted EBITDA | $5.0M | $2.2M | Improved |
| Gross margin | 59.4% | 55.3% | +410 bps |
| FY27 revenue guidance | $336M–$341M | — | Reiterated |
The quarter beat where it mattered most: profitability. Adjusted EPS of $(0.04) was materially better than the published consensus range of roughly $(0.11)–$(0.12), while revenue of $80.9 million landed around the published estimate range of approximately $80.5 million to $82.1 million. The filing says adjusted EBITDA rose to $5.0 million from $2.2 million a year earlier.
The growth engine is still working, but the portfolio is uneven. Med Tech advanced 13.2%, with Auryon up 14.7% and NanoKnife up 29.0%; AlphaVac grew 37.4%, although AngioVac declined 5.9% year over year. NanoKnife’s momentum is particularly important because probe sales rose 24.1% and capital sales rose 53.5%, suggesting adoption is expanding beyond a one-time equipment shipment.
The weaker side of the story remains the legacy business. Med Device revenue was essentially flat at 1.4% growth, meaning the company’s 6.9% consolidated growth depended heavily on Med Tech. That makes the strategic transition clearer, but it also means the newer platforms must continue carrying the business while the older portfolio contributes little incremental growth.
Margin improvement was real, but partly helped by a temporary item. Gross margin reached 59.4%, up 410 basis points, supported by pricing and the mix shift toward Med Tech; however, tariff refunds contributed $1.2 million, and margin would have been 57.8% without that benefit. 〔0〕 Management also expects gross margin to be lower in the second half of fiscal 2027, so the unusually strong first-quarter margin should not be treated as the full-year run rate.
The filing does not raise the bar for the rest of the year. Fiscal 2027 revenue, Med Tech growth, adjusted EBITDA, adjusted EPS, and gross-margin guidance were all reiterated rather than increased. 〔1〕 That is consistent with a beat in the quarter, not a broader upgrade to the outlook.
Two strategic developments add value but are not yet financial contributors. The FDA authorized the 40-patient RELIEF feasibility study testing NanoKnife for benign prostatic hyperplasia, expanding the platform’s potential beyond oncology, but the commercial opportunity still depends on trial execution and eventual regulatory progress. Separately, Eric Honroth will replace retiring CEO Jim Clemmer on November 2, 2026; the transition was partly anticipated because Clemmer’s retirement had already been disclosed, while the successor and handoff details are the new information.
Bottom line: This was a modest earnings beat built on continued Med Tech execution and better profitability, not a change to the full-year outlook. The business is advancing toward its higher-growth portfolio, but flat Med Device sales, temporary tariff help, and the CEO transition keep the signal from being a broad upgrade.
Eric Honroth becomes CEO on November 2, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!